CG Oncology reports Q3 EPS (57c), consensus (55c)

Reports Q3 revenue $1.666M, consensus $72.56k. “I am proud of the meaningful progress we have made over the last few months, most notably, the initiation of our BLA submission of cretostimogene for our lead indication of HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease. With cretostimogene’s unique profile, we remain committed to advancing a robust clinical, regulatory, and technical strategy designed to support an optimized label and expansion into additional indications-positioning cretostimogene as a potential backbone therapy for a broad range of NMIBC patients,” said Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology (CGON). “We look forward to sharing additional data from BOND-003 Cohort P and CORE-008 Cohort A before year-end.”